Mineralys Therapeutics, Inc.
MLYS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001933414
In the last 90 days, Mineralys Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 225 institutions reported holding it in 13F filings for Q2 2026, worth $2.69B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:24 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Mar 12, 2026 | Feb 12, 2025 | Mar 21, 2024 |
| Operating expenses | $170.6M | $192.4M | $84.7M |
| Research and development | $132.0M | $168.6M | $70.4M |
| Selling, general and administrative | $38.6M | $23.8M | $14.3M |
| Operating income | -$170.6M | -$192.4M | -$84.7M |
| Income tax | $0 | – | – |
| Net income | -$154.7M | -$177.8M | -$71.9M |
| EPS, basic | $-2.29 | $-3.66 | $-1.99 |
| EPS, diluted | $-2.29 | $-3.66 | $-1.99 |
| Weighted shares, basic | 67.7M | 48.5M | 36.2M |
| Weighted shares, diluted | 67.7M | 48.5M | 36.2M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Mar 12, 2026 | Feb 12, 2025 | Mar 21, 2024 |
| Cash and equivalents | $172.9M | $114.1M | $49.3M |
| Total current assets | $661.4M | $205.4M | $249.1M |
| Property, plant and equipment | $38.0K | $53.0K | – |
| Total assets | $661.8M | $205.9M | $251.6M |
| Accounts payable | $2.02M | $479.0K | $601.0K |
| Total current liabilities | $15.1M | $14.6M | $10.5M |
| Shareholders' equity | $646.7M | $191.3M | $241.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Mar 12, 2026 | Feb 12, 2025 | Mar 21, 2024 |
| Operating cash flow | -$142.4M | -$166.3M | -$81.2M |
| Capital expenditures | $15.0K | $96.0K | – |
| Free cash flow | -$142.4M | -$166.4M | – |
| Depreciation and amortization | $59.0K | $43.0K | – |
| Stock-based compensation | $19.3M | $11.3M | $5.06M |
| Investing cash flow | -$389.8M | $115.0M | -$160.5M |
| Financing cash flow | $591.0M | $116.1M | $203.2M |
| Net change in cash | $58.8M | $64.8M | -$38.4M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 29, 2026 | 88.6M | +11.9% | SEC |
| Aug 3, 2026 | 88.4M | +33.4% | SEC |
| Apr 27, 2026 | 82.5M | +26.6% | SEC |
| Mar 5, 2026 | 82.4M | +65.3% | SEC |
| Nov 3, 2025 | 79.1M | +59.0% | SEC |
| Aug 7, 2025 | 66.3M | +33.3% | SEC |
| May 8, 2025 | 65.2M | +31.3% | SEC |
| Feb 7, 2025 | 49.8M | +0.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.